Randomized trial of botulinum toxin to prevent pes cavus progression in pediatric charcot-marie-tooth disease type 1A

Muscle and Nerve

Volumn 42, Issue 2, 2010, Pages 262-267

  Burns, Joshua ^a,b   Scheinberg, Adam ^b,c   Ryan, Monique M ^d   Rose, Kristy J ^b   Ouvrier, Robert A ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c Victorian Paediatric Rehabilitation Service   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Botulinum toxin; Charcot Marie Tooth disease; Foot and ankle deformity; Hereditary motor and sensory neuropathy; Muscle imbalance; Pes cavus

Indexed keywords

BOTULINUM TOXIN;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOOT MALFORMATION; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MALE; OUTCOME ASSESSMENT; PES CAVUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADOLESCENT; BOTULINUM TOXINS; CHARCOT-MARIE-TOOTH DISEASE; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; FOOT DEFORMITIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MUSCLE STRENGTH; NEUROTOXINS; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 77955133635     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21685     Document Type: Article

References (28)

1. Burns J, Landorf KB, Ryan MM, Crosbie J, Ouvrier RA. Interventions for the prevention and treatment of pes cavus. Cochrane Database Syst Rev 2007;4:CD006154.
2. Burns J, Ryan MM, Ouvrier RA. Evolution of foot and ankle manifestations in children with CMT1A. Muscle Nerve 2009;39:158-166.
3. Burns J, Ouvrier R. Pes cavus pathogenesis in Charcot-Marie-Tooth disease type 1A. Brain 2006;129:E50-E51.
4. Mann RA, Missirian J. Pathophysiology of Charcot-Marie-Tooth disease. Clin Orthop Relat Res 1988;234:221-228.
5. Sabir M, Lyttle D. Pathogenesis of pes cavus in Charcot-Marie-Tooth disease. Clin Orthop Relat Res 1983;175:173-178.
6. Price AE, Maisel R, Drennan JC. Computed tomographic analysis of pes cavus. J Pediatr Orthop 1993;13:646-653. (Pubitemid 23235740)
7. Gallardo E, Garcia A, Combarros O, Berciano J. Charcot-Marie-Tooth disease type 1A duplication: spectrum of clinical and magnetic resonance imaging features in leg and foot muscles. Brain 2006;129:426-437. (Pubitemid 43164366)
8. Holmes JR, Hansen ST Jr. Foot and ankle manifestations of Charcot- Marie-Tooth disease. Foot Ankle 1993;14:476-486. (Pubitemid 23317062)
9. Tynan MC, Klenerman L, Helliwell TR, Edwards RH, Hayward M. Investigation of muscle imbalance in the leg in symptomatic forefoot pes cavus: a multidisciplinary study. Foot Ankle 1992;13:489-501. (Pubitemid 23039058)
10. Graham HK, Aoki KR, Autti-Ramo I, Boyd RN, Delgado MR, Gaebler-Spira DJ, et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 2000;11:67-79. (Pubitemid 30069488)
11. Bottos M, Benedetti MG, Salucci P, Gasparroni V, Giannini S. Botulinum toxin with and without casting in ambulant children with spastic diplegia: a clinical and functional assessment. Dev Med Child Neurol 2003;45:758-762. (Pubitemid 37304065)
12. Koman L, Brashear A, Rosenfeld S, Chambers H, Russman B, Rang M, et al. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 2001;108:1062-1071.
13. Burbaud P, Wiart L, Dubos JL, Gaujard E, Debelleix X, Joseph PA, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996;61:265-269.
14. Kurtis MM, Floyd AG, Yu QP, Pullman SL. High doses of botulinum toxin effectively treat disabling up-going toe. J Neurol Sci 2008;264:118-120.
15. Radovic PA, Shah E, Radovic PA, Shah E. Nonsurgical treatment for hallux abducto valgus with botulinum toxin A. J Am Podiatr Med Assoc 2008;98:61-65.
16. Delatycki MB, Holian A, Corben L, Rawicki HB, Blackburn C, Hoare B, et al. Surgery for equinovarus deformity in Friedreich's ataxia improves mobility and independence. Clin Orthop Relat Res 2005;430:138-141. (Pubitemid 40096143)
17. Rousseaux M, Launay MJ, Kozlowski O, Daveluy W. Botulinum toxin injection in patients with hereditary spastic paraparesis. Eur J Neurol 2007;14:206-212. (Pubitemid 46148310)
18. Shy ME, Chen L, Swan ER, Taube R, Krajewski KM, Herrmann D, et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 2008;70:378-383. (Pubitemid 351653401)
19. Redmond AC, Crosbie J, Ouvrier RA. Development and validation of a novel rating system for scoring standing foot posture: the Foot Posture Index. Clin Biomech (Bristol, Avon) 2006;21:89-98. (Pubitemid 41728097)
20. Cain LE, Nicholson LL, Adams RD, Burns J. Foot morphology and foot/ankle injury in indoor football. J Sci Med Sport 2007;10:311-319. (Pubitemid 47285790)
21. Menz HB, Munteanu SE. Validity of 3 clinical techniques for the measurement of static foot posture in older people. J Orthop Sports Phys Ther 2005;35:479-486.
22. Davids JR, Gibson TW, Pugh LI. Quantitative segmental analysis of weight-bearing radiographs of the foot and ankle for children: normal alignment. J Pediatr Orthop 2005;25:769-776.
23. Wearing SC, Urry S, Perlman P, Smeathers J, Dubois P. Sagittal plane motion of the human arch during gait: a videofluoroscopic analysis. Foot Ankle Int 1998;19:738-742. (Pubitemid 28523227)
24. Bennell K, Khan KM, Matthews B, De Gruyer M, Cook E, Holzer K, et al. Hip and ankle range of motion and hip muscle strength in young novice female ballet dancers and controls. Br J Sports Med 1999;33:340-346. (Pubitemid 29460610)
25. Burns J, Redmond A, Ouvrier R, Crosbie J. Quantification of muscle strength and imbalance in neurogenic pes cavus, compared to health controls, using hand-held dynamometry. Foot Ankle Int 2005;26:540-544. (Pubitemid 40944207)
26. Rose KJ, Burns J, Ryan MM, Ouvrier RA, North KN. Reliability of quantifying foot and ankle muscle strength in very young children. Muscle Nerve 2008;37:626-631. (Pubitemid 351590554)
27. Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A. Fifteen-year experience in treating blepharospasm with botox or dysport: same toxin, two drugs. Neurotox Res 2009;15:224-231.
28. Bakheit AM, Bakheit AMO. Botulinum toxin in the management of childhood muscle spasticity: comparison of clinical practice of 17 treatment centres. Eur J Neurol 2003;10:415-419.